본문 바로가기
KERD
논문KCI 등재

A Review of Gender-Affirming Hormone Therapy for Transgender and Gender Diverse Adults in South Korea

Eun Sil Lee|오정원|Yeoul Yun
대한폐경학회 (Korean Society Of Menopause)|2022.12|대한폐경학회지 (Journal of Menopausal Medicine)|제28권 제3호|pp. 92-102|DOI 10.6118/jmm.22039

0

조회

0

다운로드

1

인용

0

참고문헌

키워드

TransgenderFeminizingGender incongruenceGender-affirming treatmentMasculinizing

초록

Recently, gender-affirming hormone therapy for gender incongruence has become an issue in various countries and organizations with various guidelines. In South Korea, several clinical treatments are also used with many possible options. These treatments include masculinizing (female-to-male [FTM]) or feminizing (male-to-female [MTF]) hormone therapies, with regimens usually driven by standards of hormonal replacement therapy for hypogonadism (i.e., hypogonadal natal men and postmenopausal women). This cross-sex hormone therapy can change patients’ physical appearance to better match their gender identity and expression. Regarding masculinizing therapy, injection and transdermal gel types of testosterone are used according to international guidelines. Progesterone is utilized in the form of oral pills, injections, or intrauterine devices to suppress menstruation and avoid pregnancy. Essentially, feminizing therapy uses androgen blockers along with estrogen. This is because estrogen alone cannot exert sufficient androgen-suppressing effects. In South Korea, the most commonly used androgen blockers are spironolactone and cyproterone acetate. Gonadotropin-releasing hormone (GnRH) agonist is also available. Regarding estrogen, oral pills, injections, and transdermal gels are utilized. This review introduces these gender-affirming hormone therapies in South Korea and discusses the side effects of each regimen.

Abstract

Recently, gender-affirming hormone therapy for gender incongruence has become an issue in various countries and organizations with various guidelines. In South Korea, several clinical treatments are also used with many possible options. These treatments include masculinizing (female-to-male [FTM]) or feminizing (male-to-female [MTF]) hormone therapies, with regimens usually driven by standards of hormonal replacement therapy for hypogonadism (i.e., hypogonadal natal men and postmenopausal women). This cross-sex hormone therapy can change patients’ physical appearance to better match their gender identity and expression. Regarding masculinizing therapy, injection and transdermal gel types of testosterone are used according to international guidelines. Progesterone is utilized in the form of oral pills, injections, or intrauterine devices to suppress menstruation and avoid pregnancy. Essentially, feminizing therapy uses androgen blockers along with estrogen. This is because estrogen alone cannot exert sufficient androgen-suppressing effects. In South Korea, the most commonly used androgen blockers are spironolactone and cyproterone acetate. Gonadotropin-releasing hormone (GnRH) agonist is also available. Regarding estrogen, oral pills, injections, and transdermal gels are utilized. This review introduces these gender-affirming hormone therapies in South Korea and discusses the side effects of each regimen.

참고문헌 (70)

  1. "Standards of care version 7. Standards of care for the health of transsexual, transgender, and gender nonconforming people" (2012)[URL]
  2. "International classification of diseases 11th revision" (2022)[URL]
  3. Leinung MC, "Endocrine treatment of transsexual persons : extensive personal experience", Endocr Pract, 19, pp.644~650 (2013)
  4. Coleman E, "Standards of care for the health of transgender and gender diverse people, version 8", Int J Transgend Health, 23(Suppl 1), pp.S1~S259 (2022)
  5. Hembree WC, "Endocrine treatment of gender-dysphoric", gender-incongruent persons: an endocrine society clinical practice guideline, 2017, pp.102, 3869~3903
  6. T᾿Sjoen G, "European Society for Sexual Medicine position statement"Assessment and Hormonal Management in Adolescent and Adult Trans People, With Attention for Sexual Function and Satisfaction"", J Sex Med, 17, pp.570~584 (2020)
  7. Bourns A, "Guidelines for gender-affirming primary care with trans and non-binary patients", Rainbow Health Ontario, ~ (2019)
  8. Deutsch MB, "Effects of cross-sex hormone treatment on transgender women and men", Obstet Gynecol, 125, pp.605~610 (2015)
  9. Taub RL, "The effect of testosterone on ovulatory function in transmasculine individuals", Am J Obstet Gynecol, 223, pp.229.e1~229.e8 (2020)
  10. Light AD, "Transgender men who experienced pregnancy after female-to-male gender transitioning", Obstet Gynecol, 124, pp.1120~1127 (2014)
  11. Wolf CJ, "Effects of prenatal testosterone propionate on the sexual development of male and female rats : a dose-response study", Toxicol Sci, 65, pp.71~86 (2002)
  12. Irwig MS, "Testosterone therapy for transgender men", Lancet Diabetes Endocrinol, 5, pp.301~311 (2017)
  13. Fisher AD, "Cross-sex hormone treatment and psychobiological changes in transsexual persons : two-year follow-up data", J Clin Endocrinol Metab, 101, pp.4260~4269 (2016)
  14. Wierckx K, "Short-and long-term clinical skin effects of testosterone treatment in trans men", J Sex Med, 11, pp.222~229 (2014)
  15. Yeung H, "Prevalence of moderate to severe acne in transgender adults : a cross-sectional survey", J Am Acad Dermatol, 83, pp.1450~1452 (2020)
  16. Irwig MS, "Effects of testosterone on the transgender male voice", Andrology, 5, pp.107~112 (2017)
  17. Deuster D, "Voice deepening under testosterone treatment in female-tomale gender dysphoric individuals", Eur Arch Otorhinolaryngol, 273, pp.959~965 (2016)
  18. Cosyns M, "Voice in female-to-male transsexual persons after long-term androgen therapy", Laryngoscope, 124, pp.1409~1414 (2014)
  19. Nygren U, "Effects on voice fundamental frequency and satisfaction with voice in trans men during testosterone treatment-a longitudinal study", J Voice, 30, pp.766.e23~766.e34 (2016)
  20. Meyer WJ 3rd, "Physical and hormonal evaluation of transsexual patients : a longitudinal study", Arch Sex Behav, 15, pp.121~138 (1986)
  21. Grynberg M, "Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population", Reprod Biomed Online, 20, pp.553~558 (2010)
  22. Pirtea P, "Ovarian, breast, and metabolic changes induced by androgen treatment in transgender men", Fertil Steril, 116, pp.936~942 (2021)
  23. Asscheman H, "A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones", Eur J Endocrinol, 164, pp.635~642 (2011)
  24. Deutsch MB, "Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people", Center of Excellence for Transgender Health; The University of California San Francisco, ~ (2016)
  25. Chai NC, "Migraine and estrogen", Curr Opin Neurol, 27, pp.315~324 (2014)
  26. Velho I, "Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men : a systematic review", Andrology, 5, pp.881~888 (2017)
  27. Wierckx K, "Long-term evaluation of cross-sex hormone treatment in transsexual persons", J Sex Med, 9, pp.2641~2651 (2012)
  28. Defreyne J, "Prospective evaluation of hematocrit in gender-affirming hormone treatment : results from European Network for the Investigation of Gender Incongruence", Andrology, 6, pp.446~454 (2018)
  29. Nolan BJ, "Prevalence of polycythaemia with different formulations of testosterone therapy in transmasculine individuals", Intern Med J, 51, pp.873~878 (2021)
  30. Elamin MB, "Effect of sex steroid use on cardiovascular risk in transsexual individuals : a systematic review and meta-analyses", Clin Endocrinol(Oxf), 72, pp.1~10 (2010)
  31. van Kesteren PJ, "Mortality and morbidity in transsexual subjects treated with cross-sex hormones", Clin Endocrinol(Oxf), 47, pp.337~342 (1997)
  32. Getahun D, "Cross-sex hormones and acute cardiovascular events in transgender persons : a cohort study", Ann Intern Med, 169, pp.205~213 (2018)
  33. Cauley JA, "Estrogen and bone health in men and women", Steroids, 99(Pt A), pp.11~15 (2015)
  34. Singh-Ospina N, "Effect of sex steroids on the bone health of transgender individuals : a systematic review and metaanalysis", J Clin Endocrinol Metab, 102, pp.3904~3913 (2017)
  35. Shao T, "Breast cancer in female-to-male transsexuals : two cases with a review of physiology and management", Clin Breast Cancer, 11, pp.417~419 (2011)
  36. Rifka SM, "Interaction of digitalis and spironolactone with human sex steroid receptors", J Clin Endocrinol Metab, 46, pp.338~344 (1978)
  37. Burinkul S, "Anti-androgenic effects comparison between cyproterone acetate and spironolactone in transgender women : a randomized controlled trial", J Sex Med, 18, pp.1299~1307 (2021)
  38. Dittrich R, "Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist", Exp Clin Endocrinol Diabetes, 113, pp.586~592 (2005)
  39. Libecco JF, "Finasteride in the treatment of alopecia", Expert Opin Pharmacother, 5, pp.933~940 (2004)
  40. Goldstein Z, "Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy", J Blood Med, 10, pp.209~216 (2019)
  41. Wilson R, "Effects of high dose oestrogen therapy on circulating inflammatory markers", Maturitas, 62, pp.281~286 (2009)
  42. Prior JC, "Progesterone is important for transgender women's therapy-applying evidence for the benefits of progesterone in ciswomen", J Clin Endocrinol Metab, 104, pp.1181~1186 (2019)
  43. Iwamoto SJ, "Letter to the Editor : "Progesterone is important for transgender women᾿s therapy-applying evidence for the benefits of progesterone in ciswomen"", J Clin Endocrinol Metab, 104, pp.3127~3128 (2019)
  44. Nolan BJ, "Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy : a prospective controlled study", Endocr Connect, 11, pp.e220170~ (2022)
  45. Patel KT, "Progestogen use in gender-affirming hormone therapy : a systematic review", Endocr Pract, 28, pp.1244~1252 (2022)
  46. Rossouw JE, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results from the Women᾿s Health Initiative randomized controlled trial", JAMA, 288, pp.321~333 (2002)
  47. 윤여울, "Effect of Cross-Sex Hormones on Body Composition, Bone Mineral Density, and Muscle Strength in Trans Women", 대한골대사학회지, 28(1), pp.59~66 (2021), 대한골대사학회
  48. Jiang DD, "Effects of estrogen on spermatogenesis in transgender women", Urology, 132, pp.117~122 (2019)
  49. Jindarak S, "Spermatogenesis abnormalities following hormonal therapy in transwomen", Biomed Res Int, 2018, pp.7919481~ (2018)
  50. Alford AV, "Successful ejaculatory sperm cryopreservation after cessation of long-term estrogen therapy in a transgender female", Urology, 136, pp.e48~e50 (2020)
  51. de Blok CJM, "Sustained breast development and breast anthropometric changes in 3 years of gender-affirming hormone treatment", J Clin Endocrinol Metab, 106, pp.e782~e790 (2021)
  52. Wierckx K, "Clinical review : breast development in trans women receiving cross-sex hormones", J Sex Med, 11, pp.1240~1247 (2014)
  53. "ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism", Obstet Gynecol, 121, pp.887~890 (2013)
  54. Dekker MJ, "A European Network for the Investigation of Gender Incongruence : endocrine part", J Sex Med, 13, pp.994~999 (2016)
  55. Ott J, "Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy", Fertil Steril, 93, pp.1267~1272 (2010)
  56. Kozato A, "No venous thromboembolism increase among transgender female patients remaining on estrogen for gender-affirming surgery", J Clin Endocrinol Metab, 106, pp.e1586~e1590 (2021)
  57. Gaither TW, "Postoperative complications following primary penile inversion vaginoplasty among 330 male-to-female transgender patients", J Urol, 199, pp.760~765 (2018)
  58. Elbers JM, "Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects", Clin Endocrinol (Oxf), 58, pp.562~571 (2003)
  59. Gooren LJ, "Breast cancer development in transsexual subjects receiving cross-sex hormone treatment", J Sex Med, 10, pp.3129~3134 (2013)
  60. Brown GR, "Incidence of breast cancer in a cohort of 5, 135transgender veterans", Breast Cancer Res Treat, 149, pp.191~198 (2015)
  61. Makadon HJ, "The Fenway guide to lesbian, gay, bisexual, and transgender health" (2015), The Fenway Institute
  62. Nota NM, "The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment", Brain, 141, pp.2047~2054 (2018)
  63. Ter Wengel PV, "Meningiomas in three male-to-female transgender subjects using oestrogens", progestogens and review of the literature, 2016, pp.48, 1130~1137
  64. Costa R, "The effect of cross-sex hormonal treatment on gender dysphoria individuals᾿ mental health : a systematic review", Neuropsychiatr Dis Treat, 12, pp.1953~1966 (2016)
  65. Deutsch MB, "Updated recommendations from the world professional association for transgender health standards of care", Am Fam Physician, 87, pp.89~93 (2013)
  66. 이혜민, "Experiences of and barriers to transition-related healthcare among Korean transgender adults: focus on gender identity disorder diagnosis, hormone therapy, and sex reassignment surgery", Epidemiology and Health, 40, pp.1~13 (2018), 한국역학회[DOI]
  67. YunHui An, "Korean healthcare providers’ attitude, knowledge, and behaviors regarding sexual orientation and gender identity: a cross-sectional survey", 여성건강간호학회지, 28(1), pp.65~73 (2022), 한국여성건강간호학회[DOI]
  68. 임현혜, "Gender affirmative care of transgender people: a single center’s experience in Korea", Obstetrics & Gynecology Science, 62(1), pp.46~55 (2019), 대한산부인과학회[DOI]
  69. Breslow L, "A quantitative approach to the World Health Organization definition of health : physical, mental and social well-being", Int J Epidemiol, 1, pp.347~355 (1972)
  70. Grinspan MC, "The Yogyakarta Principles plus 10: additional principles and state obligations on the application of international human rights law in relation to sexual orientation, gender identity, gender expression and sex characteristics to complement the Yogyakarta Principles. Gender Identity, Gender Expression and Sex Characteristics, to Complement the Yogyakarta Principles", Yogyakarta Principles, ~ (2017)

관련 논문AI추천

Gender affirmative care of transgender people: a single center’s experience in Korea이은실, 이정재, 임현혜, 장윤하, 최규연대한산부인과학회 · Obstetrics & Gynecology Science2019 · 제62권 제1호Experiences of and barriers to transition-related healthcare among Korean transgender adults: focus on gender identity disorder diagnosis, hormone therapy, and sex reassignment surgery김승섭, 박주영, 이혜민, 이호림, 최보경한국역학회 · Epidemiology and Health2018 · 제40권 Age of first experience of gender incongruence among transgender and non-binary individualsEun Sil Lee, Jeong-Won Oh, Seongyun Lim, Sohee Park대한산부인과학회 · Obstetrics & Gynecology Science2024 · 제67권 제1호Effect of Cross-Sex Hormones on Body Composition, Bone Mineral Density, and Muscle Strength in Trans Women김동영, 윤여울, 이은실대한골대사학회 · 대한골대사학회지2021 · 제28권 제1호Transgender youth: current conceptsStephen M. Rosenthal대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2016 · 제21권 제4호성전환여성 (남성에서 여성)을 위한 건강관리김태희, 문원실, 이해혁대한폐경학회 · 대한폐경학회지2013 · 제19권 제2호

이 간행물의 다른 논문 (8건)

Up-to-Date Knowledge on Osteoporosis Treatment Selection in Postmenopausal WomenHye Gyeong Jeong, Min Kyung Kim, Seul Ki Kim, Hee Jeung Limpp. 85-91Vaginal Laser Therapy for Stress Urinary Incontinence: A Systematic Review of Prospective Randomized Clinical TrialsAhmed Kotb, Ahmed Zakaria, Mitra Shekari, Malihe Shirzadfard Jahromi, Amene Ranjbar, Vahid Mehrnoush, Fatemeh Darsarehpp. 103-111Trabecular Bone Score as a Risk Factor of Major Osteoporotic Fracture in Postmenopausal Women: The First Study in ThailandTanawat Amphansap, Atiporn Therdyothinpp. 112-120Pattern and Predictors of Sexual Activity among Postmenopausal Women Attending a Family Medicine Clinic in Ilorin, North-Central NigeriaAdebayo Ramat Yusuf, Ismaila Aberi Obalowu, Louis Okebunor Odeigah, Abdulkadir Mohammed, Christy Olanike Ademolapp. 121-127Effectiveness of Levonorgestrel Releasing Intrauterine System in Perimenopausal Women with Heavy Menstrual Bleeding: A Prospective Study at a Teaching Hospital in IndiaJay Prakash, Sarita Tirkey, Archana Kumari, Nidhipp. 128-135
원문 보기